Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01932580 | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | completed | Phase 2 | 10 | McGill UniversityOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00560482 | Efficacy Study of ABR-215050 to Treat Prostate Cancer | completed | Phase 2 | 206 | Active Biotech ABINDUSTRY | 3 | Oct 26, 2015 | clinicaltrials |
| Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) |
| completed |
| Phase 2 |
| 10 |
| Novartis PharmaceuticalsINDUSTRY |
| 4 |
| Oct 19, 2015 |
| clinicaltrials |
| NCT00437073 | Brain Metastases In ErbB2-Positive Breast Cancer | terminated | Phase 2 | 22 | GlaxoSmithKlineINDUSTRY | 11 | Oct 15, 2015 | clinicaltrials |
| NCT00203372 | Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | completed | Phase 2 | 6 | Translational Oncology Research InternationalOTHER | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00309023 | Study of BMS-663513 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00550017 | A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) | terminated | Phase 1 / Phase 2 | 39 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT00743938 | A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | completed | Phase 2 | 141 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT01047774 | The Effect of Soy Protein on Post- Breast Cancer Surgery Pain | terminated | Phase 2 | 6 | Dr. Yoram ShirOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01948232 | Pilot Study of Perindopril in Childhood Cancer Survivors | withdrawn | Phase 2 | 0 | The Hospital for Sick ChildrenOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00229697 | Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study | completed | Phase 2 | 317 | AstraZenecaINDUSTRY | 12 | Oct 5, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01356264 | Multimodal Prehabilitation for Colorectal Surgery | completed | Phase 2 | 89 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00105950 | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer | completed | Phase 2 | 126 | GlaxoSmithKlineINDUSTRY | 8 | Sep 28, 2015 | clinicaltrials |
| NCT00791778 | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 246 | BayerINDUSTRY | 14 | Sep 28, 2015 | clinicaltrials |
| NCT01628471 | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 20 | Uman PharmaINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01678105 | A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands(DOVE) | completed | Phase 2 | 21 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy(DOVE-M) | terminated | Phase 2 | 12 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00902291 | A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 5 | Sep 14, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00570713 | An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer | completed | Phase 2 | 155 | MorphotekINDUSTRY | 5 | Sep 9, 2015 | clinicaltrials |
| NCT01441596 | Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases | completed | Phase 2 | 121 | Boehringer IngelheimINDUSTRY | 8 | Sep 7, 2015 | clinicaltrials |
| NCT00498914 | Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects | terminated | Phase 2 | 41 | Astellas Pharma IncINDUSTRY | 4 | Sep 4, 2015 | clinicaltrials |
| NCT01009775 | A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | completed | Phase 2 | 64 | Astellas Pharma IncINDUSTRY | 2 | Sep 4, 2015 | clinicaltrials |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects | completed | Phase 2 | 67 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 13 | Sep 2, 2015 | clinicaltrials |
| NCT01462695 | Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 3 | Aug 27, 2015 | clinicaltrials |
| NCT01016015 | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | completed | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2015 | clinicaltrials |
| NCT00510250 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00045513 | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00047216 | Tipifarnib in Treating Patients With Recurrent Bladder Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00052507 | Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00053924 | Perifosine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00054145 | Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00066352 | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00886132 | A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | completed | Phase 2 | 14 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00188799 | Xray Volume Imaging (Cone Beam CT) - Prostate Cancer | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Jul 16, 2015 | clinicaltrials |
| NCT00618618 | Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | completed | Phase 2 | 73 | Kythera BiopharmaceuticalsINDUSTRY | 3 | Jul 14, 2015 | clinicaltrials |
| NCT00618722 | Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat(ATX-101) | completed | Phase 1 / Phase 2 | 85 | Kythera BiopharmaceuticalsINDUSTRY | 3 | Jul 14, 2015 | clinicaltrials |
| NCT01116843 | Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT01478594 | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | completed | Phase 2 | 265 | AVEO Pharmaceuticals, Inc.INDUSTRY | 12 | Jul 8, 2015 | clinicaltrials |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 51 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 3, 2015 | clinicaltrials |
| NCT00359086 | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma | completed | Phase 2 | 74 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00372437 | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine | completed | Phase 1 / Phase 2 | 47 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials